Is larotrectinib available in China?

Larotrectinib is an innovative anti-cancer drug and a new type of drug in the field of targeted therapy. It is unique in that it specifically targets cancers that carry NTRK (neuronal growth factor receptor kinase) gene fusions.

Larotrectinib was approved for marketing by the State Food and Drug Administration of China in 2022 , but has not yet been included in medical insurance. Since it has not been launched in the country for a long time, it may be difficult to purchase it in the hospital. For specific circumstances, it is recommended to consult the local hospital pharmacy.

In foreign markets, larotrectinib has two options: original drug and generic drug. Original drugs include the German version, the American version, the European version and the Hong Kong version, and the price is about 10,000 to 20,000 yuan. In comparison, generic drugs are much cheaper. There are Lao and Bangladeshi versions of generic drugs, and the price is around two to three thousand. It is worth noting that the ingredients of original drugs and generic drugs are basically the same.

NTRK gene fusion is a rare genetic abnormality that occurs in a variety of cancers, including soft tissue sarcoma, infantile fibroma, lung cancer, etc. This gene fusion leads to the loss of control of NTRK kinase activity, which promotes abnormal cell proliferation and survival signaling, and promotes the development of tumors.

Larotrectinib precisely blocks this abnormal signaling pathway by inhibiting the activity ofNTRKkinase, thereby inhibiting the growth and spread of tumors. This targeted therapy strategy provides patients with a new, personalized treatment option, especially for those who have failed traditional treatments.

In clinical trials, larotrectinib has demonstrated significant efficacy, including tumor shrinkage, halting progression, and sometimes even achieving complete clinical responses. This makes larotrectinib an important treatment option for patients with cancers that carryNTRKgene fusions.